- Evaluation of new agents in the treatment of Waldenstrom's macroglobulinemia (WM) and Multiple myeloma.
- In particular, I am interested in evaluating new targeted biological agents and autologous transplantation approaches for plasma cell and mature B-cell disorders, such as WM. As well, I am active in developing a uniform approach to fatigue and anemia in myeloma with a focus on disease-specific exercise programs.
- Medical education in hematology
- I am interested in the evaluation of time management skills within the CanMEDS roles in hematology training and the use of handheld personal devices (PDA) for clinical training.
Christine I Chen
Curr Hematol Malig Rep. 2017 Mar 20;:
Evidence of preserved collagen in an Early Jurassic sauropodomorph dinosaur revealed by synchrotron FTIR microspectroscopy.
Nat Commun. 2017 Jan 31;8:14220
Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.
Bone Marrow Transplant. 2014 Oct 6;
Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia.
Br J Haematol. 2014 Jun;165(5):731-3
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Br J Haematol. 2013 Aug;162(4):483-8
Br J Haematol. 2013 Jun;161(6):802-10
Curr Hematol Malig Rep. 2013 Mar;8(1):7-13
J Clin Oncol. 2011 Mar 20;29(9):1175-81
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol. 2007 Apr 20;25(12):1570-5
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre